Lv5
1310 积分 2024-04-25 加入
Patient characteristics, treatment patterns, and clinical outcomes in HER2-negative early breast cancer by germline BRCA status
1个月前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
1个月前
已完结
Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial
1个月前
已关闭
Complications of Contralateral Prophylactic Mastectomy: Do They Delay Adjuvant Therapy?
1个月前
已完结
Clinical Value of Contrast-Enhanced Ultrasound in Breast Cancer Diagnosis
1个月前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
3个月前
已完结
Implementation of Bispecific Antibodies in the Community: Lessons From the ThedaCare Cancer Center Experience
3个月前
已完结
JAK inhibitors for the treatment of autoimmune and inflammatory diseases
4个月前
已完结
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases
5个月前
已完结
652 | EFFECTIVENESS AND SAFETY OF POLA‐R‐CHP REGIMEN IN PREVIOUSLY UNTREATED LOW‐RISK DLBCL: A NATIONWIDE MULTICENTER RETROSPECTIVE STUDY OF IPI 0–1 PATIENTS IN CHINA
5个月前
已完结
皖公网安备34019202002308
